[ad_1]
© Reuters. FILE PHOTO: A normal view of the BioNTech constructing the place the manufacturing of the coronavirus illness (COVID-19) vaccine has began in Marburg, Germany, November 18, 2021. REUTERS/Fabian BimmerZURICH (Reuters) – Funding group EQT (NYSE:) and members of the Struengmann household, who’re buyers in Biontech, are contemplating a joint bid for Swiss pharmaceutical group Novartis’s generics division Sandoz, German newspaper Handelsblatt reported on Friday, citing unnamed sources.
A possible supply might worth Sandoz at greater than 20 billion Swiss francs ($21.58 billion), the newspaper reported.
Novartis in October raised the prospect of divesting Sandoz after years of revamping the enterprise, as value pressures mount within the off-patent drug sector.
It mentioned on the time it had begun a strategic assessment which might “discover all choices, starting from retaining the enterprise to separation, with a purpose to decide tips on how to greatest maximize worth for our shareholders”.
The Struengmann household and EQT, who’ve already made a number of joint investments, had been seeking to carry additional buyers on board as a consortia for a possible deal, Handelsblatt reported.
EQT declined remark. Novartis didn’t instantly reply to requests by cellphone and e-mail for remark.
The Swiss drugmaker in 2019 spun off its eyecare division Alcon (NYSE:), marking the biggest Swiss inventory deal in a decade when it made its debut with a market capitalisation of greater than $25 billion.
($1 = 0.9268 Swiss francs)
Fusion Media or anybody concerned with Fusion Media is not going to settle for any legal responsibility for loss or harm because of reliance on the data together with knowledge, quotes, charts and purchase/promote alerts contained inside this web site. Please be totally knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is among the riskiest funding types attainable.
[ad_2]
Source link
